Vitex Inactine Surgery Study On Schedule Despite Suspension Of Chronic Trial
This article was originally published in The Gray Sheet
Executive Summary
Vitex expects to complete a Phase III trial of its Inactine pathogen inactivation system for red blood cells used during surgery by 2005, even though the firm has halted a separate Phase III study in chronic transfusions
You may also be interested in...
Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex
Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells
Vitex conserves
Spending cuts include 50% workforce reduction, effective Nov. 21, following recent suspension of Phase III trial of the Inactine pathogen inactivation system for chronic red blood cell transfusions (1"The Gray Sheet" Nov. 24, 2003, p. 28). "Our goal is to reduce our burn rate by approximately 50% from its previous level to approximately $3 mil. per quarter," CEO John Barr explains. With about $5.5 mil. in cash on hand, the firm is evaluating "further spending reductions" and additional financing to continue a separate Phase III trial for acute transfusions during surgery...
Vitex conserves
Spending cuts include 50% workforce reduction, effective Nov. 21, following recent suspension of Phase III trial of the Inactine pathogen inactivation system for chronic red blood cell transfusions (1"The Gray Sheet" Nov. 24, 2003, p. 28). "Our goal is to reduce our burn rate by approximately 50% from its previous level to approximately $3 mil. per quarter," CEO John Barr explains. With about $5.5 mil. in cash on hand, the firm is evaluating "further spending reductions" and additional financing to continue a separate Phase III trial for acute transfusions during surgery...